Background Sacubitril–valsartan has been widely reported for reducing the risk of
cardiovascular death and improving left ventricular remodeling in patients with heart failure …

Aims We aimed to investigate whether sacubitril–valsartan could further improve the
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …

Objective To systematically review the efficacy and safety of sacubitril and valsartan in
treating acute myocardial infarction complicated with heart failure and to observe whether it …

Background Despite coronary re-vascularization, the common complications of acute
myocardial infarction (AMI), cardiac remodeling, and heart failure (HF), is increasing …

Background Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril‐valsartan has been
recommended as one of the first‐line therapies in heart failure with reduced ejection fraction …

Background: Acute Myocardial Infarction (AMI) is a type of coronary heart disease with high
morbidity and mortality. The renin-angiotensin-aldosterone system (RAAS) is an important …

Introduction The combination of sacubitril, a neprilysin inhibitor and valsartan, an
angiotensin receptor blocker, has been proven to be a game-changer in reducing morbidity …

The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …

Patients who develop heart failure (HF) after an acute myocardial infarction (AMI) are at
higher risk of adverse fatal and nonfatal outcomes. Studies have shown sacubitril/valsartan …

To evaluate the effects and safety of sacubitril/valsartan in patients with acute myocardial
infarction (AMI), a total of four databases, including PubMed, Cochrane Library, Embase and …